First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Original Article

A.T. Shaw, T.M. Bauer, F.d. Marinis, E. Felip, Y. Goto, G. Liu, J. Mazieres, D.-W. Kim, T. Mok, A. Polli, H. Thurm, A.M. Calella, G. Peltz, and B.J. Solomon

N Engl J Med 2020;383:2018-2029

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
11/18/2020
Course expires: 
11/19/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Saturday, November 19, 2022 - 11:59pm.